Table 2.
Subgroup | Letrozole | Tamoxifen | |
---|---|---|---|
Dominant disease site: soft tissue | n | 113 | 115 |
ORR | 50% | 34% | |
Dominant disease site: bone | n | 145 | 131 |
ORR | 23% | 15% | |
Dominant disease site: viscera | n | 195 | 208 |
ORR | 28% | 17% | |
Patients who had | n | 84 | 83 |
received prior | ORR | 26% | 8% |
antiestrogen | Odds ratio (95% CI)a | 3.85 (1.50, 9.60) | |
HR-positive | n | 294 | 305 |
ORR | 33% | 22% | |
Odds ratio (95% CI)a | 1.78 (1.20, 2.60) | ||
HR-unknown | n | 159 | 149 |
ORR | 30% | 20% | |
Odds ratio (95% CI)a | 1.79 (1.10, 3.00) |
ORR, objective response rate; CI, confidence interval; HR, hormone receptor
aOdds ratios >1.0 indicate superiority for letrozole relative to tamoxifen